Already a member? Click here to login.
Already a member? Click here to login.
The Therapeutic Goods Administration (TGA) has advised that a supply shortage of Ryzodeg 70/30 FlexTouch is anticipated from 16 June 2023 for 12 months.
In its Medicine Shortage Reports Database on 5 June, the TGA states that the anticipation is due to an ‘unexpected increase in consumer demand’.
Shortage of Ryzodeg 70/30 FlexTouch, a soluble insulin product comprising insulin degludec (ultra-long-acting basal insulin) and insulin aspart (rapid-acting mealtime insulin) administered in one injection, is set to cease on 5 June 2024.
The TGA states that the Ryzodeg Penfill product is available.
In an email to health practitioners, supplier Novo Nordisk recommends people using FlexTouch switch to its Penfill product via a new device — NovoPen® 6 — provided at no cost.
The company states that it is experiencing supply constraints on its FlexTouch product due to an ‘unprecedented global demand for other medicines using the FlexTouch® delivery device’.
For more information, please refer to the shortage database by the TGA.
UPDATE on 6 July 2023: Novo Nordisk to provide CDEs with new Ryzodeg device to help shortage
The Therapeutic Goods Administration (TGA) has advised that a supply shortage of Ryzodeg 70/30 FlexTouch is anticipated from 16 June 2023 for 12 months.
In its Medicine Shortage Reports Database on 5 June, the TGA states that the anticipation is due to an ‘unexpected increase in consumer demand’.
Shortage of Ryzodeg 70/30 FlexTouch, a soluble insulin product comprising insulin degludec (ultra-long-acting basal insulin) and insulin aspart (rapid-acting mealtime insulin) administered in one injection, is set to cease on 5 June 2024.
The TGA states that the Ryzodeg Penfill product is available.
In an email to health practitioners, supplier Novo Nordisk recommends people using FlexTouch switch to its Penfill product via a new device — NovoPen® 6 — provided at no cost.
The company states that it is experiencing supply constraints on its FlexTouch product due to an ‘unprecedented global demand for other medicines using the FlexTouch® delivery device’.
For more information, please refer to the shortage database by the TGA.
UPDATE on 6 July 2023: Novo Nordisk to provide CDEs with new Ryzodeg device to help shortage
